Login +0086-27-65522453 [email protected]

Baricitinib Catalog No : 51908

Chemical Information

Product NameBaricitinib
Iupac Chemical Name3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]- 
SynonymsBaricitinib;LY3009104;INCB028050 
Molecular FormulaC16H17N7O2S 
Molecular Weight371.42 
SmileC(C)S(=O)(=O)N1CC(C1)(CC#N)N1N=CC(=C1)C=1C2=C(N=CN1)NC=C2
InChiKeyXUZMWHLSFXCVMG-UHFFFAOYSA-N
InChiInChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
Cas1187594-09-7

Technical Data

Appearancewhite solid 
Purity98% 
Solubility5mg/ml in DMSO 
Storage3 years -20ºCpowder 
Shipping ConditionShipped under ambient temperature. 
Quality control

Description

Baricitinib (also known as LY3009104 or INCB028050) is a novel and potent small molecule inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2. Baricitinib is currently in clinical development for the treatment of rheumatoid arthritis (RA) and other inflammatory disorders.
Baricitinib is already in Phase III for RA and in Phase II for psoriasis and diabetic nephropathy.

 

Chemical Structure

51908 - Baricitinib | CAS 1187594-09-7

Package

SizePrice
Login to get price

Quick Order

Change

Contact Us